Physician profile
Priya Jaisinghani
NPI 1942738547
$239,392.64
in general payments reported to CMS, 2019-2025
19 companies · $172K in 2025
The $172K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $657 · 2023: $3,081 · 2024: $64K · 2025: $172K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $172K · Travel and Lodging: $29K · Food and Beverage: $18K · Consulting Fee: $14K · Honoraria: $5,715 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $171,568.44 |
| Travel and Lodging | $29,483.16 |
| Food and Beverage | $17,961.54 |
| Consulting Fee | $13,942.50 |
| Honoraria | $5,715.00 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $134,490.66 | 2022-2025 | Zepbound, Mounjaro, Taltz |
| Novo Nordisk INC | $81,080.40 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Novo Nordisk As | $8,409.70 | 2025 | |
| Corcept Therapeutics | $7,466.84 | 2023-2025 | Korlym |
| Eli Lilly and Company | $4,753.30 | 2024-2025 | Mounjaro |
| Madrigal Pharmaceuticals | $867.32 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $584.82 | 2024-2025 | Jardiance |
| Insulet Corporation | $423.03 | 2023-2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $327.17 | 2024-2025 | Recorlev |
| Abbott Laboratories | $290.93 | 2024-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $234.77 | 2024 | |
| Perspectum Diagnostics Ltd | $102.50 | 2025 | |
| Amgen INC. | $92.78 | 2022 | |
| Viiv Healthcare Company | $80.26 | 2024-2025 | Apretude |
| Medtronic, INC. | $79.79 | 2022-2025 | Mycarelink, Inpen Smart Insulin Delivery System, Minimed 780g |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $39.19 | 2022-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $34.75 | 2025 | Pifeltro |
| Tandem Diabetes Care, INC. | $19.44 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $14.99 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Jaisinghani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.